{"entity":{"id":"gs-0201","kind":"drug","name":"GS-0201","aka":[],"tldr":"GS-0201 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.","summary":"Gilead describes GS-0201 as a PARP1 inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. NCT06167317 is recruiting and tests GS-0201 alone and with sacituzumab govitecan, connecting PARP dependency with TROP-2-directed delivery.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06167317","url":"https://clinicaltrials.gov/study/NCT06167317"},{"label":"Primary publication or sponsor source","url":"https://www.gilead.com/science/pipeline"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06167317"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Small-molecule PARP1 inhibitor","mechanism":"Gilead describes GS-0201 as a PARP1 inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gs-0201/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"trial":[{"id":"nct06167317","kind":"trial","name":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","route":"/trials/nct06167317/"}]}}